However, the discovery of IR as a new BACE1 substrate (Meakin et al., 2018a) reveals that BACE1-inhibiting strategies may have the advantage of alleviating peripheral insulin resistance and reducing DM-associated AD risks (Figure 1). This evidence concerns the gene BACE1 and Alzheimer disease.